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Abstract 
Background: Endothelial and smooth muscle cells are considered promising resources for regenerative medicine 
and cell replacement therapy. It has been shown that both types of cells are heterogeneous depending on the type 
of vessels and organs in which they are located. Therefore, isolation of endothelial and smooth muscle cells from 
tissues relevant to the area of research is necessary for the adequate study of specific pathologies. However, sources 
of specialized human endothelial and smooth muscle cells are limited, and the search for new sources is still relevant. 
The main goal of our study is to demonstrate that functional endothelial and smooth muscle cells can be obtained 
from an available source—post-surgically discarded cardiac tissue from the right atrial appendage and right ventricu-
lar myocardium.
Methods: Heterogeneous primary cell cultures were enzymatically isolated from cardiac explants and then grown in 
specific endothelial and smooth muscle growth media on collagen IV-coated surfaces. The population of endothelial 
cells was further enriched by immunomagnetic sorting for CD31, and the culture thus obtained was characterized by 
immunocytochemistry, ultrastructural analysis and in vitro functional tests. The angiogenic potency of the cells was 
examined by injecting them, along with Matrigel, into immunodeficient mice. Cells were also seeded on character-
ized polycaprolactone/chitosan membranes with subsequent analysis of cell proliferation and function.
Results: Endothelial cells isolated from cardiac explants expressed CD31, VE-cadherin and VEGFR2 and showed typi-
cal properties, namely, cytoplasmic Weibel-Palade bodies, metabolism of acetylated low-density lipoproteins, forma-
tion of capillary-like structures in Matrigel, and production of extracellular matrix and angiogenic cytokines. Isolated 
smooth muscle cells expressed extracellular matrix components as well as α-actin and myosin heavy chain. Vascular 
cells derived from cardiac explants demonstrated the ability to stimulate angiogenesis in vivo. Endothelial cells prolif-
erated most effectively on membranes made of polycaprolactone and chitosan blended in a 25:75 ratio, neutralized 
by a mixture of alkaline and ethanol. Endothelial and smooth muscle cells retained their functional properties when 
seeded on the blended membranes.
Conclusions: We established endothelial and smooth muscle cell cultures from human right atrial appendage and 
right ventricle post-operative explants. The isolated cells revealed angiogenic potential and may be a promising 
source of patient-specific cells for regenerative medicine.
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Background
Endothelial cells (EC) and smooth muscle cells (SMC) are 
two major cell types of blood vessels. EC and SMC are 
necessary for normal circulation and involved in differ-
ent physiological processes, including angiogenesis, blood 
pressure control, coagulation, and inflammation [1–4]. 
The study of EC and SMC is important for understanding 
the aetiology and treatment of cardiovascular and other 
diseases, including cancer and diabetes, since endothelial 
dysfunction is the basis of a broad range of pathologies [5]. 
Both EC and SMC are considered promising resources for 
regenerative medicine and cell replacement therapy [6–21].
Different cultures of endothelial and smooth muscle 
cells are used as models for studies of diseases. In vivo EC 
have high functional and structural heterogeneity depend-
ing on vessel type (artery, vein or lymphatic) and tissue [3, 
14, 22–25]. Endothelial heterogeneity manifests in embry-
onic development, and a cytokine-dependent signalling 
axis, along with the influence of the extracellular matrix 
and mechanical forces, drives this process further in the 
postnatal period. Indeed, it has been shown that EC and 
SMC isolated from various organs express defined pat-
terns of transcription factors, angiogenic cytokines, adhe-
sion molecules and chemokines [3, 14, 22, 23, 26–28] 
that are essential to meet metabolic needs and adapt the 
cell to the organ environment. Therefore, isolation of EC 
and SMC from tissues relevant to the area of research is 
necessary for adequate study of specific pathologies [29]. 
In addition, endothelial cells and their precursors are 
regarded as a promising source for regenerative medicine 
to treat pathological conditions such as cardiac infarction, 
muscle ischaemia, and bone fractures [13]. Generation 
of sufficient vascular networks is also crucial for wound 
healing and successful tissue engineering.
It has been shown that the injection of EC and SMC 
in ischaemic organs leads to the formation of new blood 
vessels and promotes the recovery of the vascular net-
work. The regenerative potential of endothelial cells is 
enhanced by smooth muscle cells [30, 31]. Revasculariza-
tion after injection of EC and SMC may be of a paracrine 
nature due to release of specific angiocrine factors that 
stimulate angiogenesis [9, 15, 25].
Many researchers are currently seeking clinically rele-
vant cell sources for the isolation of postnatal endothelial 
cells, endothelial progenitor cells [6, 13, 29, 32–36] and 
smooth muscle cells [7, 16, 17, 19–21]. However, sources 
of specialized human EC and SMC are limited, and the 
search for new sources is still relevant.
More than 20 years ago, two groups of authors devel-
oped methods for isolating human endothelial cells from 
the heart of the recipient during cardiac transplantation 
to study rejection of the donor organ [37, 38]. However, 
this source is limited and may not be useful for regenera-
tive purposes.
The aim of this study is to evaluate the use of primary 
human material rich in both EC and SMC, namely, right 
atrial appendage and ventricular cardiac tissues dis-
carded during surgery. The atrial appendage is tradition-
ally used as a source of c-kit-positive cardiac stem cells 
[39, 40]. Additionally, in cultures derived from the atrial 
appendage, the presence of EC and SMC markers has 
been shown previously [41]. The main goal of our study 
is to show that functional endothelial and smooth mus-
cle cells can be obtained from an available source—surgi-
cal discarded cardiac tissue from right atrial appendage 
and right ventricular myocardium. We established a 
method for isolation, culture and enrichment of EC and 
SMC from cardiac tissues. This method yields a signifi-
cant number of cells (up to 106) when they are cultured 
for 14 days in specific growth media for endothelial and 
smooth muscle cells. This amount is sufficient for mag-
netic sorting of CD31-positive endothelial cells. Endothe-
lial and smooth muscle cells derived from human right 
atrial appendage and right ventricular myocardium may 
be a promising source of patient-specific cells for regen-
erative medicine purposes, especially for patients who 
face the prospect of surgical reoperation. For example, 
one application of endothelial cells is the development 
of cell-seeded vascular grafts, especially those under 
6  mm in diameter [8, 42]. As an example of what cells 
isolated by the proposed method may be used for tissue 
engineering, we seeded the cells on a biodegradable scaf-
fold—a polycaprolactone/chitosan (PCL/CH) blended 
membrane.
We believe that the right atrial appendage and right 
ventricular myocardium can be used as a promising 
patient-specific source of EC and SMC. We think that 
our findings will be useful to scientists working towards 




All procedures with human material were approved by 
the ethical board of the State Research Institute of Cir-
culatory Pathology, Ministry of Healthcare of the Russian 
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Federation (permit No. 45 by 26.12. 2014), and all donors 
signed an informed consent form. The animal tests were 
conducted in an SPF vivarium and were approved by the 
Institute of Cytology and Genetics of the Siberian Branch 
of the Russian Academy of Sciences (IC&G SD RAS) eth-
ical board (permit No. 22.4 by 30.05.2014).
Cell isolation and culture
Cells were isolated from post-surgically discarded sam-
ples of human right atrial appendage and right ventri-
cle myocardium as follows: the tissue was mechanically 
ground into pieces (1–3  mm3) and then enzymatically 
treated in 0.1% collagenase NB solution (Life Technolo-
gies, USA) at 37  °C for 30 min. After that, the resulting 
mixture of cells and debris was centrifuged at 300g for 
5  min and seeded in plastic dishes coated with human 
collagen IV (Sigma, USA) in culture media specific for EC 
or SMC–EGM-2 (Endothelial Cell Growth Medium-2) or 
SmGM-2 (Smooth Muscle Growth Medium-2) (both—
Lonza, Switzerland). Cell culture was maintained in 
5% CO2 at 37  °C with 1:2–1:3 passaging using TrypLE 
Express enzyme (Life Technologies, Denmark). The 
medium was replaced completely every other day; half 
of the culture medium was replaced daily. When primary 
cell culture in EGM-2 reached a monolayer, 106 cells were 
sorted using magnetic MicroBeads (130-091-935, Milte-
nyi Biotec, Germany) conjugated with antibodies against 
human CD31. The procedure of magnetic-activated cell 
sorting (MACS) was conducted according to the manu-
facturer’s instructions.
Preparation of chitosan/PCL polymer membranes
Chitosan/PCL membranes for cell seeding were prepared 
as described earlier [43–45] with certain modifications. 
Stock solutions were made: 1) 1 wt% chitosan with 85% 
deacetylation degree (Sigma–Aldrich, USA) in 0.5 M ace-
tic acid, 2) 10 wt% PCL in glacial acetic acid, and 3) the 
additional dilutions of PCL listed below, also prepared 
in glacial acetic acid. Resulting PCL stock solutions were 
mixed with 3 ml of 1% chitosan to obtain the following 
combinations in a total volume of 10 ml:
PCL25 (PCL:chitosan 1:3) =  10  ml 0.1% PCL +  3  ml 
1% chitosan
PCL50 (PCL:chitosan 1:1) =  10  ml 0.3% PCL +  3  ml 
1% chitosan
PCL75 (PCL:chitosan 3:1) =  10  ml 0.9% PCL +  3  ml 
1% chitosan
The obtained solutions (PCL25, PCL50, PCL75) were 
poured onto culture dishes (2 ml/10 cm2) and allowed to 
air-dry in a thermostat (55 °C) for 24 h until film forma-
tion. Membranes on dishes were neutralized for 30 min 
either with alkaline (0.5 M NaOH [2% w/v] for 30 min) 
or with alkaline/ethanol mixture (0.5  M NaOH in 80% 
ethanol followed by 3 washes in 80% ethanol). Finally, 
dishes with membranes were washed in PBS (phosphate-
buffered saline), UV-sterilized for 40 min and placed in a 
CO2 incubator with 5% CO2 at 37 °C.
Immunofluorescent staining of cells
Passage 1 EC and SMC were grown to confluence on 
plastic dishes or on chitosan/PCL membranes. After 
that, they were fixed with 4% PFA (paraformaldehyde) 
for 10  min, permeabilized with 0.05% Triton X-100 for 
10  min, and blocked with 1% BSA (bovine serum albu-
min). The cells were stained with primary antibodies 
overnight at 4  °C, washed with PBS and incubated with 
secondary antibodies for 1  h at room temperature. The 
stained cells were analysed with an inverted fluorescence 
microscope (Nikon Ti-E) using Nikon AR software.
The following primary antibodies were used: anti-
human CD31 (M0823, DAKO, 1:50), anti-α-SMA 
(DAKO, M0851, 1:50), anti-smooth muscle myosin heavy 
chain 11 (Abcam, ab82541, 1:500), anti-human CD90 
(eBioscience, 14090982, 1:100), anti-Von Willebrand fac-
tor (Abcam, ab6994, 1:200), anti-fibronectin (Abcam, 
ab6328, 1:200), anti-elastin (Abcam, ab21610, 1:200), and 
anti-collagen IV (Life Span, 1:200).
The following secondary antibodies were used: Alexa 
Fluor 568 goat anti-mouse IgG1 (Life Technologies, 
A21124, 1:400), Alexa Fluor 488 goat anti-mouse IgG1 
(Life Technologies, A21121, 1:400), Alexa Fluor 568 goat 
anti-mouse IgG2a (Life Technologies, A21134, 1:400), 
Alexa Fluor 568 goat anti-mouse IgG (H + L) (Life Tech-
nologies, A11031, 1:400), and Alexa Fluor 488 goat anti-
mouse IgG (H + L) (Life Technologies, A11029, 1:400).
Flow cytometry quantitative analysis of cell populations
Cells in EGM-2 were used for fluorescence-activated 
cell sorting (FACS) analysis at the second passage 
before MACS and at the third passage after separation 
of CD31+ cells by MACS. Cells in SmGM-2 were used 
for FACS analysis at the second and fifth passages. The 
viability of cells was assessed by Trypan Blue (T10282, 
Invitrogen, USA) using a Countess Automated Cell 
Counter (C10227, Korea) and was more than 95%. The 
cells were detached with enzyme-free cell dissociation 
buffer (13151014, Gibco). Non-fixed cells were used for 
direct staining by fluorochrome-conjugated antibod-
ies: anti-human CD31-APC (17-0319-42, eBioscience), 
anti-human VEGFR2-PE (560494, BD Biosciences), and 
anti-human CD90 (17-0909-42, eBioscience). Isotype-
matched antibodies served as negative control. For 
indirect staining with anti-α-SMA antibodies (DAKO, 
M0851), cells were fixed with 4% PFA for 10 min, per-
meabilized with 0.1% TWEEN for 20  min, blocked 
with 1% BSA and incubated with primary antibodies 
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overnight at 4 °C. Then, the cells were washed with PBS 
and incubated with Alexa Fluor 488 goat anti-mouse 
IgG (H  +  L) (Life Technologies, A11029) secondary 
antibody for 1  h at room temperature. The secondary 
antibody without the primary antibody was used as 
negative control. Cell populations were analysed on a 
FACS Canto II device using FACS Diva software. Assays 
were run in triplicate, and the data are presented as the 
mean ± standard deviation. Antibody dilutions and cell 
preparations were made according to the manufactur-
er’s instructions.
Analysis of endothelial cell ultrastructure
Endothelial cells from passage 2 were cultured on spe-
cific plastic films (Agar Scientific, Essex, UK) for 2, 4 
and 8 days after MACS separation. EC attached to the 
films were fixed with 2.5% glutaraldehyde in cell culture 
medium for 15 min at room temperature and removed 
to a fresh solution of 2.5% glutaraldehyde in 0.1  M 
sodium cacodylate (pH 7.4) for 1 h incubation at room 
temperature with light agitation. Cells were washed 
three times for 5  min each in 0.1  M sodium caco-
dylate and post-fixed for 1  h in a 1% aqueous solution 
of osmium tetroxide containing 0.8% (w/v) of potas-
sium ferricyanide (K3[Fe(CN)6]). After being washed 
with deionized water, the samples were incubated 
overnight at 4  °C in a 1% aqueous solution of uranyl 
acetate. The next day, the cells were washed once with 
deionized water, dehydrated in an ethanol series (30%, 
50%—5  min, 70%, 96%—10  min, 100%—15  min) and 
acetone (twice, 20  min), and embedded in Agar 100 
Resin (Agar Scientific, Essex, UK). Final polymerization 
of samples was induced by a 3-day incubation at 60 °C. 
Semi-thin sections were obtained with a Reichert-Jung 
Ultracut microtome, stained with methylene blue and 
analysed with a Zeiss Axioskop 40 light microscope. 
Ultra-thin sections were made using a Leica Ultracut 
microtome and stained with Reynolds lead citrate. Sec-
tions were examined with a JEOL JEM-100SX trans-
mission electron microscope at the Interinstitutional 
Center for Microscopic Analysis of Biological Objects 
(IC&G SD RAS, Novosibirsk, Russia).
Cytokine pattern analysis
A total of 106 sorted and unsorted EC were grown in 
EGM-2 for 24 h on 10 cm dishes. After that, the medium 
was removed, the cells were washed with PBS three 
times, and unsupplemented basal EBM was added for 
120  h to obtain conditioned medium. Cytokine pat-
tern (vascular endothelial growth factor, VEGF; stro-
mal cell-derived factor 1α, SDF1α; hepatocyte growth 
factor, HGF; epidermal growth factor, EGF; fibroblast 
growth factor 2, FGF2) was analysed by enzyme-linked 
immunosorbent assay (ELISA) using Quantikine kits 
(R&D Systems, USA).
Functional characteristics of EC and SMC in a Matrigel plug 
model
An in  vivo Matrigel angiogenesis assay was conducted 
as previously described [25, 46]. Female immunodefi-
cient (severe combined immunodeficiency, SCID) mice 
(6–8  weeks, 22–28  g) were used for experiments. Ani-
mals were kept in the SPF vivarium of the IC&G SD RAS 
(Novosibirsk, Russia). EC and SMC were used at passage 
5–7, and 5 × 105 cells in 50 µl PBS were mixed with 50 µl 
of Matrigel (BD Biosciences, USA) immediately before 
injection. A total of 100 µl of suspension was injected sub-
cutaneously into the abdominal area of the animal. The 
animals (n = 15) were divided into three groups: a control 
group receiving only PBS (n = 5), a Matrigel + EC group 
(n = 5) and a group that received a Matrigel + EC/SMC 
1:1 mixture injection (n =  5). The endothelial cells were 
labelled with vital MitoTracker Deep Red FM (M22426, 
Molecular Probes, USA). The animals were sacrificed 
after 14 days. The Matrigel plug was isolated and frozen in 
TissueTek (Sakura, USA), and 10 µm sections of the vas-
cularized implant were obtained on a Leica HM550 cry-
otome (Leica, Germany). Prepared sections were stained 
with fluorescently tagged isolectin B4 to visualize the vas-
culature, and isolectin-positive structures were captured 
in 10 fields of view (FOVs) on a Nikon Ti-E microscope. 
Structure counts were obtained using Angio Tool soft-
ware [47], and the results were analysed using a Wilcoxon 
test with the Bonferroni correction in R version 3.3.1 (R 
Core Team, Austria) [48]. Representative photos were 
performed using confocal microscope LSM 780 NLO 
(Zeiss) at the Microscopy Center of the Institute of Cytol-
ogy and Genetics, SB RAS, Russia.
Fluorescent in situ hybridization (FISH)
Pretreatment of cryosections before FISH
Slides with cryosections were incubated in xylene for 
10 min followed by rehydration in 100% ethanol 2 times 
for 5 min and 90, 80, 70–75, 50% ethanol for 5 min each. 
Then, the slides were washed in PBS for 15 min and incu-
bated in 1% Triton X-100 overnight. The next day, the 
slides were washed in PBS for 15 min, transferred into a 
Coplin jar with prewarmed (80 °C) 10 mM sodium citrate 
buffer in a water bath, and incubate for 1  h. The slides 
were washed by soaking into a Coplin jar with PBS fol-
lowed by incubation in prewarmed (37  °C) 0.01% pep-
sin for 10  min. Then, the slides were transferred into a 
Coplin jar with 1% BSA and washed in 2X SSC (saline-
sodium citrate) 2 times for 5 min followed by incubation 
in Triton X-100 (0.7%)/HCl (0.1  N). Finally, the slides 
were washed in 2X SSC 2 times for 5 min.
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Probe preparation
Human Cot-1 DNA (15279011, Thermo Fisher Scientific) 
and mouse Cot-1 DNA (18440016, Thermo Fisher Scien-
tific) were labelled with biotin 16-dUTP (11093070910, 
Roche) or digoxigenin-11-dUTP (11558706910, Roche) 
in 30 PCR cycles by DOP-PCR (degenerate oligonucle-
otide-primed PCR) with MW6 primer [49]. Human and 
mouse Cot-1 DNA and labelled probes (100 ng of each) 
were mixed with 1 mg/ml salmon sperm DNA, followed 
by addition of 2 volumes of 100% ethanol and complete 
desiccation in a speed vac. The desiccated probes were 
dissolved in 10  µl of hybridization solution containing 
50% formamide, 10% dextran sulphate, 2X SSC (1X SSC: 
0.15  M NaCl, 0.015  M sodium citrate, pH 7.0), and 1% 
TWEEN 20 for 1 h at 37 °C in a water bath. The probes 
were denatured in the hybridization solution for 5 min at 
75 °C and transferred to ice quickly.
Slide preparation, in situ hybridization and washes
The slide-mounted cryosections were denatured in pre-
warmed 70% formamide/2X SSC for 20  min at 70  °C 
followed by incubation in 2X SSC for 2 min. The slides 
were dried at room temperature (r.t.). Ten microlit-
ers of probe was pipetted onto a prewarmed coverslip 
and picked up with a slide followed by incubation in a 
humid chamber in a water bath at 37 °C overnight. The 
next day, the slides were washed in 2X SSC/50% for-
mamide 4 × 3 min at 37 °C in a water bath, then in 2X 
SSC 4 × 3 min at 37 °C and transferred to 4X SSC/0.1% 
TWEEN 20 at r.t.
Detection
Biotinylated probes were detected with a fluorescein-
avidin (A-2011, Vector Laboratories)/biotinylated anti-
avidin system (BA-0300, Vector Laboratories) and 
digoxigenin-labelled DNA was visualized with anti-
digoxigenin rhodamine Fab fragments (11207750910, 
Roche). The nuclei were counterstained with 
40,6-diamino-2-phenylindol in antifade (Vectashield, 
H-1200, Vector Laboratories) and then visualized using a 
Nikon Ni-E microscope.
XTT proliferation assay
Endothelial cells were seeded at a density of 2.5*104/
cm2 in EGM-2 on plastic or chitosan/PCL membranes. 
Endothelial cell proliferation on chitosan/PCL was 
estimated by an XTT test (2,3-bis-(2-methoxy-4-ni-
tro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) 
(11465015001, Roche, USA) according to the manufac-
turer’s instructions at 22 h after the reagents were added. 
The results were estimated using a scanning spectropho-
tometer 2030 Multilabel Reader Victor X3 (Perkin-Elmer, 
USA) at 490 nm wavelength.
Evaluation of EC angiogenic potential in 3D Matrigel 
tubulogenesis assay
CD31+  (positive) sorted EC were stained with the vital 
mitochondrial dye TMRM (tetramethylrhodamine, 
methyl ester) (Life Technologies, USA) and cultured until 
40–60% confluence. After that, the growth medium was 
aspirated and a 1:1 mixture of Matrigel (BD Biosciences, 
USA) with growth medium was prepared on ice. The 
obtained mixture was poured on top of the cells, and 
after 24  h of incubation, the formation of capillary-like 
structures was observed. Pictures were obtained on an 
inverted fluorescence microscope (Nikon Ti-E) by the 
Z-stack method, applying the Advanced Research soft-
ware 6D module.
Cell seeding and viability assay
The proliferation of EC on different surface types was 
estimated by cell counts obtained at 1, 8 and 12 days after 
seeding on different matrices. The cells were labelled with 
TMRM vital mitochondrial dye (Life Technologies, USA) 
or NucBlue vital nuclear dye (Life Technologies, USA). 
Cells were counted in 5 random FOVs with a 10× objec-
tive using an inverted fluorescence microscope (Nikon 
Ti-E, Nikon, Japan) and NIS Advanced Research software 
(Nikon, Japan). All experiments were conducted in tripli-
cate for statistical analysis.
Preparation of sections from membranes seeded 
with endothelial cells
For histological study, we chose CD31+  EC cultured 
on PCL75 membranes, which were fixed with 4% PFA 
as described above. The membrane with fixed cells was 
separated from the dish with tweezers and frozen in Tis-
sueTek; after that, 10  µm sections were prepared on a 
Cryostat Microm HM 550 (Microm International GmbH, 
Germany) in the Multiple-access Center for Microscopy 
of Biological Subjects (Institute of Cytology and Genet-
ics, Novosibirsk, Russia).
Statistical analysis
RStudio version 3.3.1 [48] and Microsoft Excel version 
14.0.6023.1000 were used for data analysis. Data are 
presented as the mean  ±  SD. The Wilcoxon test, with 
Bonferroni correction where required, was used for com-
parison between the two groups. p < 0.05 was considered 
significant.
Results
Specific enrichment of primary culture from cardiac 
explants for EC and SMC
Human cardiac explants consist of many cell types. The 
goal of our study was to establish separate endothelial and 
smooth muscle cell cultures from right atrial appendage 
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and right ventricle myocardium explants. Thus, enzymat-
ically derived cells and the remaining explant tissue were 
divided into two equivalent parts. One part was placed 
into the specific medium for the growth of endothelial 
cells (EGM-2), and the other into the medium for the 
growth of smooth muscle cells (SmGM-2).
Primary culture cell morphology is shown in Fig.  1a, 
and further analysis by immunostaining detected expres-
sion of CD31 and α-smooth muscle actin (αSMA) in 
EC and SMC, respectively, cultured in specific media 
(Fig.  1b). Flow cytometry results showed that, prior 
to sorting, the proportion of CD31-positive endothe-
liocytes in primary culture grown on EGM-2 comprised 
16.1  ±  2.1% (Fig.  1c, left panel), and 44.7  ±  2.5% of 
those cells were detected to be CD90 positive, hinting 
at a mesenchymal stem cell-like phenotype [50]. How-
ever, another major population comprising 61.9 ±  3.6% 
showed expression of αSMA, which is a key SMC marker 
(Fig. 1c, left panel). The presence of significant amounts 
of nonspecific cell populations made it necessary to 
enrich the culture of endothelial cells by sorting. CD31 
was chosen as a marker for enrichment to ensure a high 
enough quantity of mature EC.
After enrichment for EC by magnetic sorting, another 
round of FACS detected 72.6 ± 3.3% CD31-positive cells 
in the culture (Fig. 1c, left panel, Additional file 1: Table 
S1), which was maintained for at least 10 passages (data 
not shown). Furthermore, after sorting, the proportion 
of VEGFR2 (vascular endothelial growth factor receptor 
2)-positive cells increased tenfold from 6.2 ± 1.6% in the 
unsorted population to 60.4  ±  2.5%, and mesenchymal 
marker CD90-positive cells dropped to a marginally trace 
level, as did α-SMA-positive cells. The results of immu-
nofluorescent staining (Fig.  2a) also confirmed popula-
tion enrichment of cells expressing mature EC-specific 
markers–CD31 and von Willebrand factor (vWF).
Correct endothelial cell monolayer formation also 
requires production of specific extracellular matrix compo-
nents. Immunofluorescent staining showed that cells after 
enrichment of the EC population produced high levels of 
the matrix proteins fibronectin and collagen IV (Fig. 2b).
As for the primary culture that was grown in SmGM-
2, even without sorting, we found that a majority of cells 
expressed an SMC marker (α-SMA), and this remained 
the case for more than 10 passages. Our FACS data indi-
cated that at passage 5 96.1 ±  2.2% of cells cultured in 
SmGM-2 were α-SMA positive (Fig.  1c, right panel; 
Additional file 1: Table S1). It should be emphasized that, 
in FACS, a very low percent of endothelial marker-pos-
itive cells was detected under these culture conditions, 
and by passage 5 they completely disappeared. Further-
more, the quantity of CD90-positive cells decreased as 
well. However, as for CD90-positive cells, they composed 
18.9 ± 2.7% of the population in SmGM-2 at passage 5, 
and immunostaining of cells maintained in SmGM-2 
showed vivid production of smooth muscle myosin heavy 
chain (SMMHC) and elastin, a crucial component of vas-
cular extracellular matrix component (Fig. 2c).
Immunosorted cells from cardiac explants show 
ultrastructural and functional properties of mature EC
Using transmission electron microscopy, we demonstrated 
the presence of endothelial-specific microvesicles—Wei-
bel-Palade bodies (WPBs)—in sorted CD31+  cells’ cyto-
plasm (Fig.  3). We managed to detect WPB formation 
(maturation) dynamics in endothelial cells in  vitro. For 
that purpose, cells were analysed on the 2nd, 4th and 8th 
days after magnetic sorting. The early stages of WPB for-
mation from the Golgi apparatus were detected on the 2nd 
day after EC sorting (Fig. 3a, middle and right). On the 4th 
day after sorting, we observed immature bodies with small 
numbers of folded vWF structures (Fig.  3b, left) as well 
as mature ones containing significant numbers of vWF 
(Fig.  3b, middle and right) in the cytoplasm of the cells. 
On the 8th day after sorting, we detected WPB membrane 
fusion with the cytoplasmic membrane and secretion of 
vWF-folded structures to the extracellular space (Fig. 3c).
Moreover, we have shown that sorted endothelial cells 
were able to metabolize acetylated low-density lipoprotein 
(acLDL), a characteristic ability of endothelial cells [51].
The other test is based on the ability of endothelial cells 
to form tubule capillary-like structures in Matrigel. The 
in vitro tubule assay is routinely and extensively used as a 
functional test for endothelial cells. It is regarded as rep-
resentative of in vivo capillary development [52, 53]. We 
have shown that sorted endothelial cells actively formed 
capillary-like structures in a 3D assay using Matrigel 
(Fig. 4a). The formed capillary-like structures were found 
to be CD31-positive after being fixed and stained by anti-
bodies against the EC surface marker CD31.
We also assayed conditioned medium samples from 
unsorted culture and enriched EC populations for angi-
ogenic cytokines. Evaluation of the profile of selected 
cytokines illustrates the functionality of sorted endothe-
lial cells in their ability to induce paracrine effects 
[54–56]. ELISA results show a statistically significant 
decrease of VEGF and HGF content in conditioned 
medium obtained from the CD31-enriched population 
(Fig.  4b; Additional file  1: Table S2). Opposite to this, 
SDF-1a and EGF content was increased after EC enrich-
ment compared to unsorted culture (Fig. 4b; Additional 
file  1: Table S2). Regarding FGF-2, a trend towards 
decrease of this cytokine was observed in sorted EC con-
ditioned medium, but it was statistically insignificant 
(109.53 ± 8.19 pg/ml in unsorted vs 101.28 ± 7.75 pg/ml 
in sorted endothelial cells; p = 0.274).
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In vivo test for angiogenic potential of vascular cell 
cultures from cardiac explants
The vascularization of a subcutaneously injected Matrigel 
mixed with tested cells was used to examine their angio-
genic potential in  vivo. The Matrigel plug assay is cur-
rently a conventional test confirming the functionality 
of endothelial and smooth muscle cells in  vivo [57, 58]. 
The formation of networks of EC tubes is a process that 
appears to be specific to these cells and mimics the for-
mation of capillary networks in vivo [59].
An enriched culture of CD31-positive EC was tagged 
with a vital dye (MitoTracker Deep Red) to visualize 
Fig. 1 Cells isolated from cardiac explants in culture. a Morphology of primary cells migrated from cardiac explants. Phase contrast images of cells 
cultivated in an endothelial growth medium (left panel) and cells derived in a smooth muscle growth medium (right panel). Scale bar 100 μm.  
b CD31-positive endothelial (left panel) and αSMA-positive smooth muscle (right panel) cells were detected by immunofluorescent staining of 
primary cardiac explant cultures growing in endothelial or smooth muscle medium, respectively. Scale bar 100 μm. c Flow cytometric analysis of 
surface markers. Comparison of cells cultivated in endothelial growth medium before and after MACS separation (left panel). Comparison of cells 
cultivated in smooth muscle cell growth medium at the second and fifth passages (right panel)
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injected cells. Viable cells were visualized in the area of 
injection after 14 days with a Kodak In-Vivo Multispec-
tral Imaging System device (Fig. 4c), and vasculature was 
visualized in frozen sections of Matrigel plugs stained 
with isolectin B4. Fluorescent isolectin-positive capil-
lary structures were present on day 14 after implanta-
tion (Fig.  4c) quantitative analysis revealed that vessel 
counts were significantly higher in specimens where 
Matrigel was mixed with CD31-enriched cardiac explant 
cells compared to the control of Matrigel mixed with the 
plain vehicle, PBS (Fig.  4d; 164 ±  57 vs 33 ±  15 struc-
tures/FOV; p =  0.0005). In histology preparations from 
Matrigel plugs that contained a mix of EC and SMC, this 
parameter reached a maximum value of 508 ± 38 struc-
tures/FOV, which was higher than in either EC or acellu-
lar transplants (Fig. 4d).
To evaluate human cell retention, we used FISH in 
prepared Matrigel + EC + SMC sections and detected 
transplanted human and host murine cell nuclei 
(Fig.  4e). Note that enhancement of angiogenesis after 
Fig. 2 Properties of endothelial and smooth muscle cells after selection. a Endothelial cells at second passage after enrichment by MACS separa-
tion reveal CD31- and vWF-positive staining and produce extracellular matrix (collagen IV- and fibronectin-positive staining) (b). c Smooth muscle 
cells at the fifth passage reveal αSMA- and SMMCH-positive staining and produce extracellular matrix elastin. Scale bar 100 μm
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injection of cells is considered a paracrine effect of 
injected cells [9, 15, 25]. In studies, the angiogenic 
potential of injected cells is tested by this method. The 
human injected cells remaining at 14 or more days 
after the injection have been visualized by either HNA 
antibodies or human CD31-specific antibodies. In our 
experiment, we have shown the presence of the remain-
ing injected human cells by FISH, because this method 
is reliable, detects species-specific DNA repeats and 
does not require matching antibodies to prevent anti-
bodies made in mice from cross-precipitating to mouse 
cells on the slide.
Endothelial and smooth muscle cell application 
on polycaprolactone and chitosan membranes: 
Proliferation and viability investigation
Based on previously established protocols for manufac-
ture of chitosan/PCL membranes [8, 43, 45, 60–65], we 
prepared several membranes with different chitosan/
PCL ratios (see Materials and Methods for details) (Addi-
tional file 2: Figure S1a). In the process of mixture mak-
ing, the source components are solved in acetic acid, and 
the final polymer membranes are neutralized by alkaline 
solution. Recent data suggest that mammalian cells pro-
liferate more actively on chitosan surfaces neutralized by 
Fig. 3 Dynamics of Weibel-Palade body (WPB) formation in the cytoplasm of endothelial cells, as analysed by transmission electron microscopy.  
a General view of endothelial cell ultrastructure; scale bar 5 µm (left). Early stage of WPB formation from Golgi apparatus in the cells on the 2nd day 
after sorting (middle and right); scale bar 100 nm. b Immature WPBs with small quantities of folded vWF structures (left) and mature WPBs containing 
significant amounts of vWF (middle and right) detected on the 4th day after sorting; scale bar 100 nm. c The secretion of vWF-folded structures from 
mature WPBs to the extracellular space on the 8th day after sorting; scale bar 100 nm. WPBs are indicated by the arrowhead
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Fig. 4 Functional properties of cardiac explant-derived cells. a Endothelial cells form capillary-like structures in Matrigel, uptake acLDL (left) and 
demonstrate a CD31-positive phenotype (middle). A merged image is represented in the picture on the right. Scale bar 100 μm. b Angiogenic 
cytokine profiles of conditioned medium obtained from cardiac explant-derived cells before and after MACS separation of CD31-positive cells. 
Wilcoxon test. c Evaluation of functional properties of CD31-positive endothelial cells in vivo. Visualization of injected mix (Matrigel + cells with the 
vital dye MitoTracker Deep Red FM) after 14 days with a Kodak In-Vivo Multispectral Imaging System device (left). Vasculature in cryosections of the 
Matrigel plug at day 14 after injection of Matrigel only, Matrigel + endothelial cells and Matrigel + endothelial + smooth muscle cells is detected 
by isolectin B4 Alexa 594 conjugate staining. Scale bar 100 μm. d A diagram representing the number of vessels positive for isolectin B4 Alexa 594 
conjugate staining (red colour) as determined under a fluorescence microscope in 10 random fields of view. Wilcoxon test with Bonferroni correc-
tion. * vs Matrigel only, p = 0.0005; ** vs Matrigel + endothelial cells, p = 0.00003. e Fluorescent in situ hybridization of human and mouse DNA 
probes (hCot and mCot, respectively) to cryosection of Matrigel + EC + SMC. Human probes (green) are distributed evenly over the nuclei, whereas 
mouse probes (red) are detected in discrete dots due to the structure of α-satellite repeats in a mouse genome. Nuclei are counterstained with DAPI
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alkali mixed with ethanol rather than after neutralization 
by alkali alone [44]. The neutralization method affects the 
nanostructure of the resulting polymer’s fibres, which, in 
turn, influences the membrane surface topography and 
the populated cells’ adhesive capacity [66]. Thus, chitosan 
membrane neutralization by NaOH solution in 80% eth-
anol gives advantages in mouse fibroblast adhesion and 
proliferation compared to neutralization by aqueous 
NaOH solution. However, that fact was not explored for 
PCL and chitosan mixtures. It is also known that the ratio 
of PCL-chitosan mixture components affects cell prolif-
eration dynamics [67, 68].
Our comparative data using both types of neutrali-
zation procedure shows that after 12 days of culture on 
PCL25 chitosan/PCL membranes treated with a mixture 
of NaOH/ethanol, CD31+  -sorted EC showed signifi-
cantly better proliferation dynamics compared to NaOH 
neutralization (p < 0.01, Figure S1b in Additional file 2). 
A similar trend was observed for PCL50 and PCL75, but 
this difference did not reach statistical significance at any 
timepoint (Fig. 5b; Additional file 2: Figure S1b).
As for differences between different chitosan/PCL 
membranes treated with NaOH/ethanol, PCL25 showed 
optimal performance compared to PCL50 and PCL75 
(p < 0.01). In the case of alkaline neutralization this was 
not reproducible, and we observed comparable prolif-
eration of EC on PCL25/50/75 with a non-significant 
tendency towards a PCL25 advantage over other compo-
sitions (Additional file 2: Figure S1b).
The improvement of cell proliferation on chitosan/PCL 
membranes compared to chitosan alone (taken as 100%) 
was confirmed by XTT analysis of cells seeded on NaOH/
ethanol-treated membranes for 2, 5 or 8 days (Fig. 5c). By 
the 8th day of observation, the number of viable cells on 
PCL25 and PCL75 was significantly higher than on chi-
tosan (Fig. 5c), and on all tested membranes cell counts 
were significantly higher compared to uncoated culture 
dishes. Thus, for subsequent experiments using human 
cells seeded on membranes, we used NaOH/ethanol-
treated PCL25 membranes.
In vitro analysis of EC functional properties in PCL25 
chitosan/PCL membrane
Maximum biocompatibility of tissue-engineered con-
structs and imitation of physiological features depend 
on the seeded cells’ functional properties and the stabil-
ity of the cells’ features after they are seeded onto the 
matrix. Since cells demonstrated optimal proliferation 
and viability on PCL25 surfaces, our subsequent esti-
mations of cell functional properties were made on this 
type of membrane. Endothelial cells populated on PCL25 
retained the ability to metabolize acLDL and to form cap-
illary-like structures in the depth of 3D Matrigel culture 
(Fig. 6a). The cells composing studied tissue-engineered 
constructs retain the specific endothelial markers CD31 
and von Willebrand factor (Fig.  6b), and they also yield 
the extracellular matrix components fibronectin and col-
lagen IV (Fig. 6c). In addition, on sections of cell-seeded 
tissue-engineered constructs, the formed endothelial cell 
monolayer stained vividly for vWF (Fig. 6d). We have also 
shown that SMC keep their specific markers, αSMA and 
SMMHC, and yield elastin—a component of the extracel-
lular matrix—when populated on a surface made of the 
polycaprolactone and chitosan mixture PCL25 (Fig. 6e).
Discussion
Methods for isolation of cardiac EC and SMC have been 
described for many animal models, namely, mouse, rat, 
guinea pig, and rabbit [69–78]. All of them are based 
on either a perfusion technique or enzymatic hydrolysis 
of myocardial samples, excised from the isolated heart 
from sacrificed animals. Isolation of human cardiac 
endothelial cells was described by Gräfe et al. and McD-
ouall et al. [37, 38]. As a source of endothelial cells, they 
used explanted human hearts of recipients who under-
went cardiac transplantation. The first method requires 
a specialized perfusion system; the second was based on 
fermentative hydrolysis of chunks of ventricle from an 
explanted human heart followed by sorting with an anti-
HLADR antibody or Ulex lectin-coated magnetic beads. 
The authors emphasize the importance of studying car-
diac endothelial cells to investigate the pathophysiology/
pharmacology of cardiovascular disease [37].
The atrial appendage as a post-operative by-product 
is widely used for producing c-kit-positive cardiac stem 
cells (CSC), whose regenerative potential has been the 
focus of extensive research, including clinical trials 
(SCIPIO, CADUCEUS—see clinicaltrials.gov) [79–82]. 
We propose to use this source as well as post-operative 
myocardial material to isolate human EC and SMC, 
which can be a source of patient-specific therapeutic cell 
populations in patients who face the prospect of surgical 
reoperation.
We introduced a technique for functional endothelial 
and smooth muscle cell extraction from post-operative 
myocardial specimens taken from the right atrial append-
age and right ventricle. The proposed method includes 
the following stages: enzymatic tissue hydrolysis, cul-
ture of isolated cells on specific media on the surface of 
human collagen IV, enrichment by means of magnetic 
sorting for an endothelial population with antibodies 
against the mature endotheliocyte marker CD31, and fur-
ther cultivation on a surface processed with collagen IV 
in specific culture media.
After enrichment by means of magnetic sorting, the 
content of CD31-positive cells increases more than 
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fourfold, and the content of VEGFR2-positive cells 
increases almost tenfold in medium for endotheliocyte 
growth. Along with that, the content of CD90-positive 
cells non-specific for an endothelial population decreases 
up to 2.1  ±  2.8%, and αSMA-positive cells are lost. It 
is worth noting that in the process of primary culture 
in medium without added growth factors, endothelial 
markers are completely lost after 2–3 passages, and the 
fraction of CD90-positive cells increases up to 80% (data 
not presented). It is confirmed by a number of further 
tests that the population enriched for the endothelial 
marker CD31 represents functional endotheliocytes.
One important aspect of the functional characteriza-
tion of an endothelial population is an ultrastructural 
study for the presence of typical granules. WPBs are 
distinctive cigar-shaped granules specific to functional 
Fig. 5 Dynamics of proliferation and viability of CD31-positive endothelial cells cultured on chitosan, PCL25, PCL50 and PCL75. a Numbers of 
cells in five random fields of view (FOVs) after 1, 8 and 12 days of cultivation on membranes neutralized by alkali (NaOH). b Numbers of cells in five 
random fields of view (FOVs) after 1, 8 and 12 days of cultivation on membranes neutralized by alkali mixed with ethanol (NaOH + Et). c XTT assay 
of CD31-positive endothelial cells cultured on membranes and on untreated plastic dishes (control) for 2, 5 and 8 days. Wilcoxon test. * vs chitosan 
day 8, p < 0.01; # vs control day 8 p < 0.01
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Fig. 6 Properties of cardiac explant-derived endothelial and smooth muscle cells cultured on PCL25 membranes (except Fig. 6d) neutralized by 
alkali mixed with ethanol. a Endothelial cells cultured on PCL25 uptake acLDL (left), form capillary-like structures in Matrigel (middle cells stained 
with vital dye TMRM; right phase contrast image). Scale bar 100 μm. b Endothelial cells cultured on PCL25 retain specific endothelial markers: CD31 
(left), vWF (right). Scale bar 50 μm. c Endothelial cells cultured on PCL25 retain the ability to produce extracellular matrix (collagen IV- and fibronec-
tin-positive staining). Scale bar 50 μm. d Cryosection over cell-seeded PCL75 membrane. Monolayer of endothelial cells has vWF-positive staining. 
Scale bar 20 μm. e Smooth muscle cells cultured on PCL25 retain specific smooth muscle markers: SMMCH (left), αSMA (middle), elastin (right)
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endothelial cells [83]. WPBs contain molecules of vWF 
protein, P-selectin, and the other functional molecules 
secreted by endothelial cells in response to shifting 
microenvironment conditions [84, 85]. Thus, ultrastruc-
tural study of these cells reveals the presence and for-
mation dynamics of WPBs (Fig.  3). In mature WPBs, 
folded structures of vWF—one of the basic components 
contained in the granules—are detected. The ability of 
derived endothelial cells to produce the extracellular 
matrix components fibronectin and collagen IV, to form 
capillary-like structures in Matrigel and to metabolize 
the acetylated form of low density lipoprotein is shown in 
the present study.
In terms of the investigation of cells’ functional prop-
erties by means of ELISA, cytokine quantities were esti-
mated in conditioned medium obtained from primary 
unsorted culture, grown in EGM-2, as well as enriched 
endotheliocyte culture. The discovered decrease of 
VEGF165 in conditioned medium obtained from sorted 
cells compared to unsorted can be associated with 
two factors. First, cytokines are expressed not only by 
endothelial cells but by a number of other cell types 
(macrophages, activated T-lymphocytes and others) [86, 
87], which can be present in primary unsorted popula-
tion. Direct enrichment of endothelial cells leads to the 
loss of a significant portion of other VEGF-secreting 
cells. For example, the fraction of CD90-positive cells 
decreases more than 20-fold. Second, the decrease of 
VEGF165 content in conditioned medium from sorted 
endotheliocytes can be associated with the almost ten-
fold increase of cells containing the VEGF receptor 
VEGFR2. FACS data indicate that the VEGFR2-positive 
portion elevates from 6.2 ± 1.6% in an unsorted popula-
tion to 60.4 ±  2.5% in a sorted one. An analogous ten-
dency to decrease in conditioned medium from enriched 
endotheliocytes is observed for HGF. Additionally, an 
insignificant drop of FGF-2 level is detected. The oppo-
site tendency is revealed for SDF-1α and EGF. Their 
content in conditioned medium from sorted endothelial 
cells is reliably higher than in medium obtained from an 
unsorted cell population. A higher content of the given 
chemokines indicates the endothelial cells’ paracrine 
potential.
Functional characteristics in  vitro were confirmed 
by functional testing in  vivo on an abdominal Matrigel 
implant model in immunodeficient SCID mice. It has 
been shown by Japanese authors [9, 15], that com-
bined transplantation of human EC and mural cells 
(MC, both smooth muscle cells and pericytes) could 
markedly increase vascular regeneration compared 
to single-fraction transplantation of EC or MC. How-
ever, a transplantation of mural cells leads to less pro-
nounced revascularization compared to endothelial 
cells. Therefore, to test in  vivo the functional proper-
ties of the derived endothelial and smooth muscle cells, 
we had three experimental groups of SCID-mice: injec-
tion of endothelial cells, injection of both smooth mus-
cle endothelial cells, and PBS as a control. Injection of 
endothelial cells leads to fivefold multiplication of vascu-
lar structures detected on Matrigel implant cryosections 
in comparison with control PBS injection. After coop-
erative injection of endothelial and smooth muscle cells 
derived from human myocardium, the quantity of vascu-
lar structures increases 15-fold compared to the control 
(Fig. 4d).
We have shown by fluorescent in  situ hybridiza-
tion that cryosections of Matrigel implants contain not 
only human cells but also mouse cells, the latter to a 
larger extent (Fig. 4e). This is affirmed by paracrine fac-
tor action, which facilitates the development of vascular 
structures composed of mouse cells in response to the 
introduction of human endothelial cells.
Thus, we proposed a new source for functional 
endothelial and smooth muscle cells isolation—post-
operational material from the human right atrial append-
age and right ventricle myocardium. These cells can be 
used for the development of cell-seeded tissue-engi-
neered constructs for the purposes of vascular surgery. 
As an example of the application of both types of cells, 
we seeded them on a biodegradable scaffold—a polycap-
rolactone/chitosan (PCL/CH) blended membrane. We 
characterized the morphological and functional proper-
ties of those cells and evaluated their biological behav-
iour after seeding to chitosan/PCL membranes.
Blood vessel substitutes from biological and synthetic 
materials have been extensively developed in recent years 
[66, 88]. Vascular grafts made of polytetrafluoroethylene 
(PTFE), polyethylene terephthalate (PET), and polyure-
thanes have been widely tested, and in spite of synthetic 
materials’ positive features (accurate sizing, permeability, 
controlled structure and mechanical properties), their 
application brought unsatisfactory long-term results [88]. 
The latter is especially an issue when synthetic prosthe-
ses of small diameter are used. The complications include 
stenosis, thrombosis, neointimal hyperplasia, lack of 
vascularization and inflammation induced by polymer 
degradation products resulting in loss of structural integ-
rity [89, 90]. This problem drew researchers’ attention 
to biodegradable materials, among which chitosan and 
polycaprolactone (PCL) found wide medical application 
[60]. Using a mixture of natural (chitosan) and synthetic 
(PCL) polymers made it possible to combine positive fea-
tures of both materials [91]. Furthermore, this approach 
increases feasibility and reduces expense compared to 
standard PCL-monomer synthesis followed by polym-
erization. In a number of works, both chitosan and PCL 
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separately were found to be inferior to their combina-
tion, with optimal proportions of these components 
established and tested in membranes that were success-
fully seeded with mouse fibroblasts [45], bovine corneal 
endothelial cells [43] or human dermal microvascular 
EC [44]. The possibility of using material consisting of a 
mixture of polycaprolactone and chitosan, seeded with 
autologous peripheral blood mononuclear cells, to create 
a small diameter vessel has been demonstrated in vivo in 
a canine model [8]. However, even combined chitosan/
PCL material has been shown to have much room for 
improvement, and as a mixture of 2 polymers gave better 
functional properties, seeding these with several ex vivo 
cultured cell types can provide more reliable reproduc-
tion of the properties of blood vessels.
The proliferation dynamics and retention of specific 
functional properties of endothelial and smooth muscle 
cells of human cardiac explants, contained in tissue-engi-
neered constructs made on a base of polycaprolactone 
and chitosan, were analysed in vitro. We have shown that 
a mixture of polycaprolactone and chitosan is advan-
tageous for endothelial cell proliferation in compari-
son with 100% chitosan. The proliferation indices of the 
endothelial cells tends to be higher upon alkaline-ethanol 
solution neutralization compared to alkaline aqueous 
solution (Fig.  5b). Cells proliferate on PCL25 surfaces 
more effectively than on PCL50 or PCL75 surfaces. 
Therefore, it is preferable to use membranes with a 25:75 
ratio of PCL and chitosan, neutralized with a mixture of 
alkaline and ethanol, when creating tissue-engineered 
constructs with endothelial cells from human cardiac 
explants.
An important aspect to confirm the functionality of 
the cells growing on the scaffold is the retention of a 
typical pattern of cell antigens. It has been shown that, 
depending on the composition of the scaffold, the pat-
tern of markers may change, even to the point that some 
of them are lost entirely. For example, the integral mem-
brane protein Na–K ATPase in bovine corneal endothe-
lium, growing on substrates of mixtures with different 
ratios of PCL/CH, was only weakly detected on PCL5 
and PCL10, while levels appeared to be normal on PCL15 
and PCL25 [43]. It is reported that, when cells are grown 
on 100% chitosan, this marker is completely lost in the 
cells. It has been shown that, if human dermal micro-
vascular endothelial cells (HDMEC) are grown on the 
surface of the metal alloy Co28Cr6Mo, endothelial cells 
acquire an aberrant pattern of intracellular distribution 
of CD31, VE-cadherin, ZO-1 and F-actin [92]. In experi-
ments conducted in vivo, implants of CoCrMo-alloy dis-
rupted the integrity of the microvascular endothelium 
in the surrounding tissues and caused extensive oedema 
[93], whereas the cultivation of HDMEC on the surface of 
a titanium alloy does not lead to changes in the pattern of 
intracellular distribution of these markers [92].
We have shown in  vitro retention of specific markers 
contained in endothelial and smooth muscle cells in tis-
sue-engineered constructs on a PCL and chitosan mix-
ture. For endothelial cells grown on membranes made 
of given polymer mixtures, retention of CD31 and vWF 
was shown, along with the capacity to metabolize low-
density lipoproteins, to yield the extracellular matrix 
components collagen IV and fibronectin, and to form 
capillary-like structures in Matrigel poured onto cells sit-
ting on the membrane. For smooth muscle cells, αSMA 
and SMMHC retention was shown. Retention of cell 
functional properties in the composition of tissue-engi-
neered constructs in vitro gives grounds for the assump-
tion that populating a mixed polymer membrane would 
facilitate adequate integration to surrounding tissues and 
minimize negative remote results for vascular transplant. 
Thus, in the year 2013, a group of investigators demon-
strated the possibility of using material composed of 
a mixture of PCL and chitosan for cell-seeded vessels 
of small diameter (less than 6 mm) [8]. The nano-fibres 
utilized in scaffold formation were obtained by electro-
spinning of given polymer mixture, and then they were 
populated by autologous mononuclear cells from canine 
peripheral blood and implanted in the carotid arter-
ies of 6 dogs. Histological and immunohistochemical 
analysis of the tissue-engineered constructs, obtained 
after 3 months, showed the regeneration of endothelium 
and the presence of collagen and elastin [8]. In work on 
bovine corneal endothelium growing on membranes pre-
pared from PCL-chitosan mixture by means of evapora-
tion in a convection oven, the authors demonstrated the 
high proliferative capacities and preservation of morpho-
physiological and functional properties of endothelial 
cells in the constructs [43].
Conclusions
In the present study, we established a method for isola-
tion, culture and enrichment of endothelial and smooth 
muscle cells from post-operative cardiac tissues from the 
right atrial appendage and right ventricle. This method 
allows one to obtain a significant number of cells that 
reveal functional properties in  vitro and demonstrate 
angiogenic potential in vivo. As an example of how cells 
isolated by the proposed method may be used for tis-
sue engineering, we seeded the cells on a biodegradable 
scaffold—a membrane consisting of a blend of polycap-
rolactone and chitosan. Isolated endothelial and smooth 
muscle cells may be a promising source of patient-spe-
cific cells for regenerative medicine.
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a. A general view of Petri dishes with an untreated surface and surfaces 
with transparent membranes made of chitosan, PCL25, PCL50, PCL75. 
b. A summary diagram showing the numbers of endothelial cells in five 
random fields of view (FOVs) after 1, 8 and 12 days of cultivation on mem-
branes of chitosan, PCL25, PCL50, and PCL75 neutralized by alkali (NaOH) 
or alkali mixed with ethanol (NaOH + Et).
the Russian Federation (Permit No. 45 by 26.12. 2014), and all donors signed an 
informed consent form. The animal tests were conducted in an SPF vivarium 
and were approved by the Institute of Cytology and Genetics of the Siberian 
Branch of the Russian Academy of Sciences (IC&G SD RAS) ethical board 
(Permit No. 22.4 by 30.05.2014).
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